G-CSF mobilised peripheral blood progenitor cells have been used successfully as an alternative source for allogeneic or autologous stem cell transplantation. [1] [2] [3] It was proved first in mice and later in humans that the quality of mobilised stem cells was similar to those present in BM grafts and better than non-mobilised PBSC as regards their self-maintaining capacity, long-term repopulating capability and the number of long-term culture-initiating cells (LTC-IC). [4] [5] [6] [7] [8] Tumour cell contamination of leukapheresis products in solid tumours, especially in breast cancer patients, has been proved after mobilisation with SCF, G-CSF or GM-CSF. [9] [10] [11] [12] The pathological significance of the re-infused tumour cells in the relapses has been proved clearly first by genetic markers in neuroblastoma patients. 13 Upon mobilisation in chronic myeloid leukaemia (CML) patients, both Philadelphia positive (Ph+) and negative LTC-IC can be detected in peripheral blood 14, 15 and it was proved by genetic markers that Ph + cells contributed to relapse of CML patients after autologous bone marrow transplantation. 16 Although lymphoma or leukaemia cells are known to be present in leukapheresis products, leukaemia cell contamination may not equate to leukaemogenic stem cell contamination. This idea supports the use of animal models where colony-forming leukaemia cells in vitro (CFU-L) and cells inducing leukaemia in vivo (putative leukaemia stem cells) can be studied in parallel. In our previous experiments we studied the lymphoma cell contamination of PBSC in a murine model 17 and found that, due to the relatively little contamination, no lymphoma-associated death could be observed when PBSC were transplanted after mobilisation with cyclophosphamide (CY) or a combination of CY and G-CSF. Quite recently a murine leukaemia model 18 was offered to follow the contamination of bone marrow with leukaemia cells transduced with a retroviral vector encoding human nerve growth factor receptor. This elegant method, however, does not distinguish leukaemia stem cells from the bulk of leukaemic cells.
In the present experiments, mice bearing WEHI-3B myelomonocytic leukaemia 19 were used to study the relationship between the CFU-L content and the leukaemogenic potency (ie leukaemic stem cells) of BM cells or WBC obtained from leukaemic mice. The leukaemogenic potency of grafts was estimated in terms of the incidence of leukaemia in the recipients and, if the incidence approached or achieved 100%, in terms of survival times of leukaemic mice. In this paper the term 'leukaemogenic potency of CFU-L' is used merely to express the relationship between the leukaemogenic effect and CFU-L-content of a graft, without implying the identity of CFU-L and leukaemogenic cells. Since in clinical practice CY or CY followed by G-CSF is used to mobilise PBSC for transplantation, we also wanted to see whether treatments used to mobilise stem cells influenced the above-mentioned relationship.
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Materials and methods
Experimental animals and leukaemia induction
Twelve to 14-week-old BALB/c female mice were used. WEHI-3B cells were maintained in suspension cultures by serial passage every third day, with occasional intervals of storage in liquid nitrogen. To induce leukaemia 1 × 10 5 cells from suspension culture were injected i.p. This cell dose induced 100% mortality with a median survival time of 31 days.
Assay of granulocyte-macrophage colony forming cells (CFU-GM) and leukaemia colony-forming cells (CFU-L)
For CFU-GM assay, an agar colony culture system was used. From bone marrow 5 × 10 4 and from blood 5 × 10 5 nucleated cells were plated in McCoy's 5A medium (Gibco, Life Technologies, Vienna, Austria) supplemented with 25% horse serum (Gibco). As CSF, 10% WEHI-3B conditioned medium was used. The final concentration of agar was 0.3%. Leukaemia colony-forming cells (CFU-L) could be assayed in the absence of CSF since these cells produce IL-3. By this method normal CFU-GM and CFU-L could be assayed in parallel samples. Colonies (ie aggregates of more than 50 cells) were counted 7 days after plating.
Assay of leukaemia-inducing cells
Cells from suspension culture of WEHI-3B, blood or bone marrow cells from leukaemia bearing mice were injected over a wide dose range (2 × 10 1 to 2 × 10 6 ) into nonirradiated isologous recipients i.p. and survival was followed for 90 days.
The ED 50 value (ie size of inoculum-inducing leukaemia in 50% of the animals, a measure of leukaemia-inducing potency) was calculated according to Litchfield and Wilcoxon. 20 Differences in the incidence of leukaemia were evaluated with Fisher's test.
Mobilisation of progenitor cells and leukaemia-inducing cells
Fifteen or 22 days after leukaemia initiation 200 mg/kg cyclophosphamide (CY, Cytoxan; Bristol-Myers Squibb, Baar, Switzerland) was injected i.p. and G-CSF (recombinant human G-CSF, Neupogen; Hoffman-La Roche, Basel, Switzerland) was injected s.c. in a daily dose of 250 g, divided into two equal doses on days 3, 4, 5 and 6 after CY administration. Three hours after the last injection, mice were exsanguinated from the axillary vessels, circulating CFU-GM and CFU-L were assayed and various amounts of blood cells up to the minimum graft size for stem cell transplantation 17 were injected into unirradiated recipients.
Results
From exponentially growing suspension cultures, as few as 20 WEHI-3B cells or 10 CFU-L were capable of inducing leukaemia in some of the recipients. The ED 50 (size of inoculum inducing leukaemia in 50% of the animals, ie lethality within 90 days) was 221 (95% confidence limits, 60-813) cells, corresponding to 109 CFU-L (33-361) per mouse. Mice inoculated with у10 4 cells (у3960 CFU-L) all died. After high supralethal doses the survival time of recipients seemed to depend on the number of injected CFU-L rather than that of nucleated cells, since the survival time of the 13 mice inoculated with 10 5 cells negatively correlated with the logarithm of the number of CFU-L they had received (r = −0.9365, P Ͻ 0.001, Table 1 ).
Three weeks after the i.p. inoculation of 10 5 suspension culture-derived WEHI-3B cells the development of leukaemia was indicated by a dramatic increase in WBC and spleen weight, as well as by the appearance of large numbers of CFU-L in the BM and PB. In the pre-terminal phase (4 weeks after inoculation in a group where median survival was 31 days) the WBC reached у100 × 10 3 /l with a huge splenomegaly and a further expansion of CFU-L in the bone marrow and in the blood (Table 2) .
Following transplantation of 0.5-2.0 × 10 6 nucleated blood cells from leukaemic mice 3 weeks after inoculation of WEHI-3B cells (2 × 10 6 WBC are equivalent to the minimum graft size needed to protect supralethally irradiated recipients, 17 but we wished to see the effect of lower cell doses, too), leukaemia-associated death occurred in all but one of the 21 unconditioned recipients. When applying a mobilisation protocol mimicking the clinical situation for obtaining PBSC for autologous transplantation (CY or CY followed by G-CSF administration) 5 none of the 18 recipients died of leukaemia (P = 0.003 at 0.5 × 10 6 or 1 × 10 6 cells and P = 0.002 at 2 × 10 6 cells, Fisher's test, Table 3a ). Two million WBC obtained in the terminal phase of leukaemia (4 weeks after inoculation) from untreated leukaemic donors killed all mice grafted from this source. If the cells were obtained after mobilisation with CY or CY + G-CSF, only two of the eight mice died (P = 0.03; Table 3a ).
Three or 4 weeks after initiation of leukaemia 2 × 10 ), but failed to do so at 4 weeks (Table 3b ).
The incidence of leukaemia induced by a wide range of cells (or CFU-L) as a reference basis from various sources is shown in Tables 1 and 3a , b. CFU-L present in BM cells or WBC of untreated leukaemic mice 3 weeks after inoculation of leukaemic cells seemed to be more potent inducers of leukaemia than their counterparts derived directly from exponentially growing suspension cultures (Table 1 ). This was supported by the following: (1) The lower 95% confidence limit of the ED 50 of suspension-culture CFU-L was 33 (Table 1) ; although ED 50 for CFU-L from the abovementioned in vivo sources could not be calculated from our data, it seemed to be below 10, since eight of the 12 mice (67%) inoculated with Ͻ10 CFU-L from this source died of leukaemia (Tables 3a and 3b) . (2) Of the six mice inoculated with 54 CFU-L derived from suspension cultures, only one became leukaemic (Table 1 ). In comparison, 31
Bone Marrow Transplantation of the 36 mice inoculated with р40 CFU-L taken from the PB or BM of untreated leukaemic mice 3 weeks after the inoculation with WEHI-3B cells died of leukaemia (P = 0.0016) (Table 3a and b) . In other words, smaller numbers of CFU-L killed higher proportions of mice if CFU-L were taken from untreated leukaemic mice rather than from suspension cultures.
A second conspicuous feature of the relationship between the incidence of leukaemia and the number of CFU-L inoculated was that the leukaemogenic potency of in vivoderived CFU-L seemed to depend on the treatment of donors (none, CY or CY + G-CSF) and on the time of transplantation (3 or 4 weeks after leukaemia induction). Three weeks after the induction of leukaemia, р30. ). Actually, CFU-L in the WBC of mice in CY or CY + G-CSF groups 3 weeks after leukaemia induction seemed to be even less potent inducers of leukaemia than suspension-culture derived CFU-L: of this group, 11 mice received CFU-L numbers exceeding the ED 50 of suspension-culture CFU-L (109 CFU-L per recipient, Table 1 ) but none of them died (Table 3a) .
This was not the case, however, if BM cells of leukaemic mice were obtained at 4 weeks, ie in the terminal phase of leukaemia. Although CY treatment, as expected, greatly reduced the number of CFU-L present in the 'minimum graft size' of 2 × 10 5 BM cells, this graft induced 100% leukaemia in the recipients (Table 3b) . CFU-L present at 4 weeks in the WBC of mice treated with CY or CY + G-CSF, however, showed reduced leukaemogenic potency: the incidence of leukaemia was only 2/8 in mice grafted from this source, although the graft contained у68 CFU-L per recipient. For comparison, 14 of the 16 recipients (87%) died if given WBC of untreated leukaemic mice at 3 weeks containing р40 CFU-L per recipient (Table 3a , P = 0.0047). (Since WBC cultures of untreated donors 4 weeks after the inoculation of leukaemia showed diffuse growth of leukaemic cells, the number of inoculated CFU-L could not be determined in this group, Table 3a.) If mice were given CFU-L in numbers high enough to induce lethality approaching or achieving 100%, the incidence of leukaemia was not suitable to compare the leukaemogenic potency of the grafts. As an attempt at gaining some information about the leukaemogenic potency of grafts near to or in the supralethal range, we looked for a relationship between the median survival time and the number of CFU-L grafted. All groups were included in this analysis if the number of CFU-L in grafts of PB or BM cells was available and at least two mice in the group died within 90 days, ie of leukaemia. A significant negative correlation was found between the median survival time of leukaemic mice and the logarithm of injected CFU-L (Figure 1 ).
Discussion
Since PBSC are increasingly used for autologous transplantation, features of mobilised stem cells and their possible contamination with tumour cells are often studied. Mobilised human stem cells were shown to contain drug-resistant cells able to maintain multilineage human haemopoiesis in sublethally irradiated immunodeficient mice. 21 PBSC mobilised from CML patients, however, showed that the CD34 + Thy1 + Lin − enriched cell subpopulation contains substantial numbers of residual Ph + cells, 22 indicating the importance of a model where leukaemia-inducing cell contamination can be determined and/or qualified.
With the aim of following the leukaemia-inducing cell contamination of mobilised PBSC, a murine model was used in the present experiments as described earlier. 17 Although we were aware of the fact that CML cells show growth factor dependent growth, in order to be able to quantify contaminating leukaemia-inducing cells in WBC or bone marrow, we tried to establish a system where quantitative assay of in vitro colony-forming leukaemia cells (CFU-L) and survival rate and/or survival time of mice transplanted with WEHI-3B cells of different origin (ie from suspension culture or from WEHI-3B bearing mice) could be correlated.
A closer relationship between CFU-L and the leukaemogenic cells was suggested by the observation that the survival time of mice depended on the variable number of CFU-L in the standard inoculum of 10 5 WEHI-3B cells obtained from exponentially growing suspension cultures (Table 1) . This was further supported by the significant correlation found between the median survival time of leukaemic mice and the log-number of CFU-L inoculated from in vivo sources (Figure 1) . However, the relationship between the leukaemogenic potency and the CFU-L content of the graft seemed to depend on the source of the leukaemic cells. First, CFU-L from exponentially growing cultures were less potent inducers of leukaemia than were CFU-L taken from untreated leukaemic mice. Second, the leukaemogenic effect of cells from in vivo sources was reduced by treating the donors with CY or CY + G-CSF to an extent not explained by the concomitant reduction in the CFU-L content of the graft, if the cells were grafted 3 weeks after the induction of leukaemia (Table 3a and b, see Results). This was, however, not valid for BM cells in the terminal phase of leukaemia (4 weeks after inoculation). Neither the incidence of leukaemia (Table 3b) , nor the median survival time (closed symbols in Figure 1 ) seemed to deviate from the values predicted by the CFU-L content of grafts and the relationships based on CFU-L in untreated mice.
The above examples of the dissociation of the leukaemogenic potency and the CFU-L-content of the graft could be explained by supposing that whilst CFU-L and leukaemogenic cells (leukaemic stem cells) are associated, they are not completely identical. A closer association, even identity, cannot be excluded, however, if we take into consideration that the dissociation between the capabilities of cells to form a colony in vitro and induce leukaemia in vivo may also be based on changes in their homing capability. Such a change has recently been observed by Glimm et al 23 for normal competitive repopulating units cultured in vitro. These authors described that the engraftment potential of human haematopoietic stem cells was diminished by active proliferation in vitro and suggested that the engraftment of Bone Marrow Transplantation leukaemic stem cells may also be restricted to, or preferentially associated with, a quiescent subpopulation. In our present experiments, the decreasing order of the leukaemogenic potency of CFU-L from various sources was as follows: CFU-L from untreated leukaemic mice Ͼ CFU-L in exponentially growing suspension cultures Ͼ CFU-L taken from CY or CY + G-CSF-treated leukaemic mice 3 weeks after leukaemia induction. It can be supposed that 3 weeks after inoculation, in the advanced phase of leukaemia, leukaemic stem cells are less rapidly proliferating than in an exponentially growing culture in vitro. CY treatment, in turn, can reduce the leukaemic burden with a consequent recruitment of quiescent leukaemic stem cells into the cell cycle. If this were the case, the dissociation of the leukaemogenic potency and the CFU-L content of the graft might be explained in terms of the different proliferative state of CFU-L under different conditions.
The difference in the leukaemia-inducing ability of the minimum graft size from bone marrow or mobilised PB in pre-terminal phase of leukaemia calls attention to another possibility, namely that the adherence of leukaemiainducing cells might be different, ie leukaemia-generating cells might be less mature cells than CFU-L and may have reduced adherence to bone marrow stroma. In human CML altered adhesive properties of leukaemic blast cells have already been suggested. 24 The development of WEHI leukaemia is slower than that of some other transplantable murine leukaemias (L1210, P-388) offering a possibility to study the contamination of PBSC as a function of leukaemia burden. As early as 3 weeks after inoculation, the minimum graft size of bone marrow cells (2 × 10 5 ) and peripheral blood cells (2 × 10 6 ) from untreated leukaemic mice contained high numbers of CFU-L and generated 100% death in the recipients. Peripheral blood cells after mobilisation with CY or CY + G-CSF, however, contained fewer CFU-L and did not induce leukaemia, indicating a smaller number of leukaemogenic cells. With increasing leukaemia burden, ie 4 weeks after leukaemia induction, the minimum graft size of PBSC following mobilisation contained leukaemia-inducing cells (Table 3a) .
The present data support the idea that although CFU-L may be used as an indicator of the number of leukemogenic cells, they cannot be used as an absolute predictor of the contamination of the PBSC. At the time when these experiments were finished the elegant experiments by Garcia-Castro and co-workers 18 showed cell dose-dependent survival rate, if mice were transplanted with syngeneic bone marrow cells contaminated with graded doses of NGFr transduced WEHI cells. Combining the results of these experiments with our findings, we suggest that CFU-L can be also applied as an indicator of leukaemia development in untreated leukaemic mice, but might not be unconditionally acceptable in cytostatic-treated mice. These data have to be taken into consideration when extrapolating the data of murine experiments to human autologous PBSC transplantation. Perhaps future work on human leukaemogenic cells in a NOD/SCID model may produce further proof for the above-mentioned ideas.
